Table 1.
Patient characteristics. Study population, N = 406. ‘Tamoxifen‐only’ subgroup, n = 191. All patients received chemotherapy. Menopausal status was based on the information from case report forms within hospital records. PR, progesterone receptor; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma.
| Clinical/pathological features | Study population (n = 406) | ‘Tamoxifen‐only’ subgroup (n = 191) |
|---|---|---|
| Follow‐up time BCSS, months, mean (median) | 154.7 (163.2) | 153.7 (163.3) |
| Age, years, mean (median) | 43.7 (44.5) | 40.1 (41.0) |
| < 45, n (%) | 203 (50.0) | 191 (100) |
| 45–50, n (%) | 202 (49.8) | – |
| 50–55, n (%) | 1 (0.2) | – |
| Menopausal status, n (%) | ||
| Pre | 322 (79.3) | 166 (86.9) |
| Post | 25 (6.2) | 4 (2.1) |
| Missing | 59 (14.5) | 21 (11.0) |
| Surgery, n (%) | ||
| Mastectomy | 182 (44.8) | 88 (46.1) |
| Lumpectomy | 224 (55.2) | 103 (53.9) |
| Tumor size (pT ), n (%) | ||
| pT1 | 203 (50.0) | 96 (50.3) |
| pT2 | 178 (43.8) | 95 (49.7) |
| pT3 | 20 (4.9) | – |
| pT4 | 2 (0.5) | – |
| Missing | 3 (0.7) | – |
| Grade, n (%) | ||
| 1 | 32 (7.9) | 14 (7.3) |
| 2 | 253 (62.3) | 111 (58.1) |
| 3 | 115 (28.3) | 64 (33.5) |
| Missing | 6 (1.5) | 2 (1.0) |
| Histology, n (%) | ||
| IDC | 339 (83.5) | 171 (89.5) |
| ILC | 40 (9.9) | 13 (6.8) |
| Missing | 27 (6.7) | 7 (3.7) |
| pN, n (%) | ||
| Pos | 249 (61.3) | 115 (60.2) |
| Neg | 157 (38.7) | 76 (39.8) |
| HER2, n (%) | ||
| Pos | 33 (8.1) | 15 (7.9) |
| Neg | 234 (57.6) | 113 (59.2) |
| Missing | 139 (34.2) | 63 (33.0) |
| ER, n (%) | ||
| Pos | 406 (100.0) | 191 (100.0) |
| Neg | 0 (0.0) | 0 (0.0) |
| PR, n (%) | ||
| Pos | 350 (86.2) | 165 (86.4) |
| Neg | 50 (12.3) | 24 (12.6) |
| Missing | 6 (1.5) | 2 (1.0) |